NYSE:LLYPharmaceuticals
Has Lilly’s Obesity Drug Breakthrough Left Enough Upside After a 577% Five Year Surge?
If you are wondering whether Eli Lilly is still worth buying after its massive run up, or if the market has already priced in all the good news, you are not alone.
The stock has climbed 4.3% over the last week, 37.7% year to date, and an enormous 577.5% over five years. This naturally raises questions about how much upside is really left from here.
Recent gains have been driven largely by excitement around Eli Lilly's leadership in obesity and diabetes treatments, with blockbuster demand for...